Genzyme

October 4, 2007 -- Genzyme Corp. (NASDAQ: GENZ) announced today that it has received approval to market Elaprase® (idursulfase) in Japan for the treatment of Hunter syndrome. Elaprase is an enzyme replacement therapy developed by Shire Human Genetic Therapies Inc., and Genzyme is commercializing the product in Japan and other Asia Pacific countries under an agreement with Shire. Genzyme intends to launch Elaprase this quarter, following reimbursement approval.    » read more »

September 26, 2007 -- Genzyme Corporation (Nasdaq: GENZ) and Bayer Schering Pharma AG, Germany today announced that the first patient has been treated in the first of two planned Phase 3 trials examining the safety and efficacy of alemtuzumab for the treatment of multiple sclerosis (MS).    » read more »

Project to Support the Increasing Global Need for Genzyme Products

September 18, 2007 -- Genzyme Corp. (Nasdaq: GENZ) today broke ground on a significant expansion of its flagship manufacturing facility at Allston Landing in Boston. The $150 million project is focused on adding space for manufacturing support functions, and will allow for the creation of 90 jobs.    » read more »

August 29, 2007 -- Genzyme Corporation today announced that results from the Dialysis Clinical Outcomes Revisited (DCOR) trial, the largest outcomes study ever conducted in the hemodialysis population, have been published in Kidney International. The three-year trial involving more than 2,100 patients compared the difference in outcomes for patients receiving Renagel® (sevelamer hydrochloride) with those using calcium-based phosphate binders.    » read more »

August 9, 2007 -- Genzyme Corp. (Nasdaq: GENZ) today announced that it has reached an agreement in principle to settle a class action lawsuit brought by a group of shareholders following the consolidation of Genzyme’s tracking stock structure in 2003.    » read more »